Metabolic

GLP2 10mg

$100.00

This dual GLP-1/GIP receptor agonist reduces HbA1c levels by 1.87-2.07% in type 2 diabetes research, significantly outperforming single-hormone agents like semaglutide. Studies show 20-40% reductions in triglycerides and modest decreases in systolic blood pressure (2-7 mmHg), contributing to cardiovascular risk reduction. It improves insulin sensitivity by up to 30% while reducing fasting insulin levels, helping address the underlying metabolic dysfunction rather than just managing symptoms. Beyond diabetic complications, enhanced glucose control may protect against vascular dementia and Alzheimer's disease, as chronic hyperglycemia damages brain blood vessels. Peak blood-sugar improvements are typically observed within 12-20 weeks, with continued metabolic benefits as long as therapy continues.

For research use only. Not for human consumption. Sold individually; does not include bacteriostatic water or syringes.